MA45046A - Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules - Google Patents
Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellulesInfo
- Publication number
- MA45046A MA45046A MA045046A MA45046A MA45046A MA 45046 A MA45046 A MA 45046A MA 045046 A MA045046 A MA 045046A MA 45046 A MA45046 A MA 45046A MA 45046 A MA45046 A MA 45046A
- Authority
- MA
- Morocco
- Prior art keywords
- nanoliposomal
- irinotecan
- treatment
- small cell
- cell cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US201762474661P | 2017-03-22 | 2017-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45046A true MA45046A (fr) | 2019-03-27 |
Family
ID=59258274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045046A MA45046A (fr) | 2016-05-18 | 2017-05-17 | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (fr) |
| EP (1) | EP3458059A1 (fr) |
| JP (3) | JP2019516693A (fr) |
| KR (1) | KR20190009319A (fr) |
| CN (1) | CN109640995A (fr) |
| AU (1) | AU2017267449A1 (fr) |
| BR (1) | BR112018072988A2 (fr) |
| CA (1) | CA3023743A1 (fr) |
| IL (1) | IL262656A (fr) |
| MA (1) | MA45046A (fr) |
| MX (1) | MX2018013873A (fr) |
| PH (1) | PH12018502422A1 (fr) |
| SG (2) | SG11201809788VA (fr) |
| TW (1) | TWI791437B (fr) |
| UA (1) | UA125646C2 (fr) |
| WO (1) | WO2017199093A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| TWI724018B (zh) | 2015-08-20 | 2021-04-11 | 英商益普生生物製藥有限公司 | 用於癌症治療之組合療法 |
| JP2018528185A (ja) | 2015-08-21 | 2018-09-27 | イプセン バイオファーム リミティド | リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法 |
| RU2732567C2 (ru) | 2015-10-16 | 2020-09-21 | Ипсен Биофарм Лтд. | Стабилизированные фармацевтические композиции камптотецина |
| JP2019533684A (ja) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107712A1 (fr) * | 2004-05-03 | 2005-11-17 | Hermes Biosciences, Inc. | Liposomes utiles pour l'administration de medicaments |
| WO2009097011A1 (fr) * | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Préparations améliorées de médicaments au platine |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 MX MX2018013873A patent/MX2018013873A/es unknown
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 CA CA3023743A patent/CA3023743A1/fr active Pending
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/fr unknown
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/fr not_active Withdrawn
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Application Discontinuation
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109640995A (zh) | 2019-04-16 |
| SG11201809788VA (en) | 2018-12-28 |
| CA3023743A1 (fr) | 2017-11-23 |
| TWI791437B (zh) | 2023-02-11 |
| MX2018013873A (es) | 2019-02-14 |
| JP2019516693A (ja) | 2019-06-20 |
| US20230000858A1 (en) | 2023-01-05 |
| PH12018502422A1 (en) | 2019-03-11 |
| EP3458059A1 (fr) | 2019-03-27 |
| JP2020117548A (ja) | 2020-08-06 |
| AU2017267449A1 (en) | 2018-11-15 |
| JP2022010295A (ja) | 2022-01-14 |
| TW201740946A (zh) | 2017-12-01 |
| IL262656A (en) | 2018-12-31 |
| KR20190009319A (ko) | 2019-01-28 |
| WO2017199093A1 (fr) | 2017-11-23 |
| SG10201912407YA (en) | 2020-02-27 |
| UA125646C2 (uk) | 2022-05-11 |
| BR112018072988A2 (pt) | 2019-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
| DK3209691T3 (da) | Sammensætninger til inducering af differentiering af myeloid-afledt suppresorcelle til behandling af cancer og infektiøse sygdomme | |
| MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| BR112016027041A2 (pt) | Combinações farmacêuticas para tratamento do câncer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA47613A (fr) | Compositions et procédés de traitement du cancer | |
| DK3218005T3 (da) | Glycan-interagerende forbindelser og anvendelsesfremgangsmåder | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| DK3114215T3 (da) | Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom | |
| MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted |